>10,000× acceleration in hit discovery
Typical HTS throughput (~100,000 compounds/day), experimentally screening a 10-billion-molecule library would take ~270 years.
SAPIAN™
THE UNIVERSAL INTERACTION ENGINE
Proteome-scale interaction prediction to unlock novel, patentable hits - faster and safer.
AN ACCELERATOR
Sapian is Kantify's AI-driven Dry Lab platform for hit discovery. It predicts protein-ligand interactions across the entire eukaryotic proteome, enabling discovery teams to identify novel, IP-free chemotypes - before committing a single wet lab experiment.
Instead of computer-based docking or lab-based high-throughput screening, Sapian uses probabilistic inference to identify novel or first in class chemotypes for both druggable and traditionally "undruggable" targets without requiring crystal structures.
Because interactions are predicted globally, Sapian enables:
- Early selectivity assessment
- Built-in safety signals
- Rapid prioritization of viable scaffolds before synthesis
The result is faster hit discovery, stronger IP, and lower early-stage attrition, all through a single dry lab engine applicable across therapeutic areas.
FROM DOCKING TO DISCOVERY INTELLIGENCE
Traditional hit discovery is constrained by:
- Limited structural availability and reliability
- Local pocket modeling
- Slow, stochastic wet-lab screening
AI-powered methods have yet to master the complexity of biochemical and phenotypic reactions. This gap is most evident with undruggable targets, where traditional predictive models consistently fall short.
Sapian moves beyond these limitations by treating drug discovery as a large-scale interaction inference problem. Rather than modeling a single binding site, Sapian predicts the probability of interaction between any molecule and any protein, generating a global view of biological compatibility, identifying multiple possible novel chemotypes for a target of interest, and flagging potential off-target risks early.
We map the likelihood of a biological handshake, regardless of structures. This opens multiple opportunities.
CRACKING THE "UNDRUGGABLE"
Sapian is built as a scalable factory for small molecule discovery. Sapian's speed is achieved by an interaction model with strong generalization power across unseen chemotypes and proteins.
As a result, Sapian can infer binding likelihoods in chemical space orders of magnitude larger than any experimentally screened or structurally characterized dataset, even in the absence of structural information.
Approach
Novelty-led discovery to identify untapped chemical space.
Selectivity optimization guided by proteome-wide predictions.
Outcome
- First-in-class starting points for targets previously written off.
- Orders-of-magnitude faster hit identification at a fraction of traditional HTS cost.
SAFETY-BY-DESIGN
Because Sapian evaluates interactions globally, safety is integrated from the very beginning.
- Early hERG interaction prediction at the hit identification stage (responsible for the withdrawal of several marketed drugs);
- Removal of potential patented structures;
- Chemotypes with high cardiotoxicity risk are deprioritized before synthesis;
- ADMETox endpoint prediction (BBB, DILI, ...);
- Proteome-wide visibility enables early detection of off-target liabilities.
Outcome
Medicinal chemistry resources are focused only on scaffolds that are both biologically relevant and toxicologically viable.
WHY CHOOSE SAPIAN
IP Frontiering
Identify novel, unclaimed chemotypes in dark chemical space
→ Stronger patents and freedom to operate
Universal Scope
One engine pre-trained to tackle novel targets regardless of available data
→ Rapid target pivoting without retooling
Dry Lab Velocity
Replace months of wet-lab screening with rapid inference
→ 100× more hits per euro or dollar invested
Drugging the Undruggable
Generate hits where docking and physics fail
→ Access to first-in-class opportunities
Sapian is a versatile dry factory, which finds novel chemotypes amongst billions, even before wet-lab commitment or before IP is crowded.
HOW SAPIAN COMPARES WITH HIGH-THROUGHPUT SCREENING
Minimum 100-fold improvement in performance
Hit rate in HTS: 0.1%. Hit rate with Sapian: between 10% and 96% (target dependent, difficulty is systematically evaluated ex ante).
10,000 times more molecules evaluated
Average campaign size in big pharma: 1 million compounds. Average campaign size with Sapian: 10 billion compounds.
Contact us for a non-binding and confidential feasibility analysis for your therapeutic target before any pilot.
PARTNERSHIPS